

Institutional Review Board statement

The local Institutional Review Board approved the study as indicated below.



The University of British Columbia
Office of Research (Services) Ethics
Clinical Research Ethics Board – Room
210, 828 West 10th Avenue, Vancouver,
BC V5Z 1L8

ETHICS CERTIFICATE OF EXPEDITED APPROVAL

PRINCIPAL INVESTIGATOR: Kelly A. Lefaiivre	INSTITUTION / DEPARTMENT: UBC/Medicine, Faculty of/Orthopaedics	UBC CREB NUMBER: H13-00098				
INSTITUTION(S) WHERE RESEARCH WILL BE CARRIED OUT:						
<table border="1"><thead><tr><th>Institution</th><th>Site</th></tr></thead><tbody><tr><td>Vancouver Coastal Health (VCHRI/VCHA) Other locations where the research will be conducted: N/A</td><td>Vancouver General Hospital</td></tr></tbody></table>			Institution	Site	Vancouver Coastal Health (VCHRI/VCHA) Other locations where the research will be conducted: N/A	Vancouver General Hospital
Institution	Site					
Vancouver Coastal Health (VCHRI/VCHA) Other locations where the research will be conducted: N/A	Vancouver General Hospital					
CO-INVESTIGATOR(S): Gerard Slobogean Peter J. O'Brien						
SPONSORING AGENCIES: N/A						
PROJECT TITLE: Digital blinding of radiographs to mask treatment allocation of distal femur fractures						

THE CURRENT UBC CREB APPROVAL FOR THIS STUDY EXPIRES: March 1, 2014

The UBC Clinical Research Ethics Board Chair or Associate Chair, has reviewed the above described research project, including associated documentation noted below, and finds the research project acceptable on ethical grounds for research involving human subjects and hereby grants approval.

This approval applies to research ethics issues only. The approval does not obligate an institution or any of its departments to proceed with activation of the study. The Principal Investigator for the study is responsible for identifying and ensuring that resource impacts from this study on any institution are properly negotiated, and that other institutional policies are followed. The REB assumes that investigators and the coordinating office of all trials continuously review new information for findings that indicate a change should be made to the protocol, consent documents or conduct of the trial and that such changes will be brought to the attention of the REB in a timely manner.

DOCUMENTS INCLUDED IN THIS APPROVAL:			APPROVAL DATE: March 1, 2013															
<table border="1"><thead><tr><th>Document Name</th><th>Version</th><th>Date</th></tr></thead><tbody><tr><td>Protocol:</td><td></td><td></td></tr><tr><td>Protocol</td><td>5</td><td>December 3, 2012</td></tr><tr><td>Consent Forms:</td><td></td><td></td></tr><tr><td>Consent</td><td>2</td><td>March 1, 2013</td></tr></tbody></table>				Document Name	Version	Date	Protocol:			Protocol	5	December 3, 2012	Consent Forms:			Consent	2	March 1, 2013
Document Name	Version	Date																
Protocol:																		
Protocol	5	December 3, 2012																
Consent Forms:																		
Consent	2	March 1, 2013																

CERTIFICATION:

In respect of clinical trials:

- 1. The membership of this Research Ethics Board complies with the membership requirements for Research Ethics Boards defined in Division 5 of the Food and Drug Regulations.*
- 2. The Research Ethics Board carries out its functions in a manner consistent with Good Clinical Practices.*
- 3. This Research Ethics Board has reviewed and approved the clinical trial protocol and informed consent form for the trial which is to be conducted by the qualified investigator named above at the specified clinical trial site. This approval and the views of this Research Ethics Board have been documented in writing.*

The documentation included for the above-named project has been reviewed by the UBC CREB, and the research study, as presented in the documentation, was found to be acceptable on ethical grounds for research involving human subjects and was approved by the UBC CREB.

Approval of the Clinical Research Ethics Board by one of:

Dr. Peter Loewen, Chair
Dr. Stephen Hoption Cann, Associate Chair